World Chronic Lymphocytic Leukemia Therapeutics Market - Opportunities and Forecasts, 2014 -2022
|
A01162
|
Pages: NA
|
Jul 2020 |
1742 Views
|
|
|
|
Author(s) :
NA
|
Tables: NA
|
Charts: NA
|
Formats*:
|
|
COVID-19
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the World Chronic Lymphocytic Leukemia Therapeutics Market
Request Now !Chronic Lymphocytic Leukemia (CLL) is a type of hematological malignancy marked by excessive proliferation of abnormal white blood cells. CLL predominantly affects the B-cell lymphocytes which are involved in the production of antibodies to fight against infections and foreign antigens. Rising incidence of CLL coupled with a high rate of mortality, demonstrates the unmet market need for better therapeutics. According to the American Cancer Society (ACS) estimate, more than 14000 new cases and more than 4,500 deaths are expected in the year 2015. CLL is more common among the aging population, with a higher frequency in the people aged 70 or above.
Family history of blood disorders and excessive exposure to harmful chemicals are the two important drivers for CLL treatment market. Higher incidences of leukemia coupled with improved diagnosis for CLL, growing disease awareness and rising incidences of comorbidities, especially among elders are other factors significant in determining the market growth. Furthermore, breakthrough therapy designation by FDA and discovery of some pipeline drugs would further accelerate the market growth. However, high cost of treatment, is likely to curtail the market growth.
The global Chronic Lymphocytic Leukemia Therapeutics market is segmented on the basis of drug type, route of administration and geography. On the basis of drug type, the market is segmented into Chemotherapy, Targeted Therapies and Others. The Targeted Therapy market is further segmented into approved drugs and pipeline drugs. According to route of administration, the market is segmented into Oral drugs, Intravenous drugs and others. Geographically, the market is segmented across four regions namely North America, Europe, Asia Pacific and LAMEA.
Co-development and collaboration agreements are some of the key strategies adopted by leading market players. For instance, GlaxoSmithKline plc and Genmab A/S, have entered into co-development and collaboration agreement for drug Arzerra (ofatumumab), used in the treatment of relapsed CLL. Arzerra is a monoclonal antibody which targets CD20 molecule on the surface of CLL cells. Recently, Venetoclax, an investigational drug for the treatment of relapse or refractory CLL, has been granted Breakthrough Therapy Designation by US FDA. The drug is being developed by AbbVie in collaboration with Genentech and Roche. The companies profiled in the report include, GlaxoSmithKline Plc, Biogen Idec, Genentech Inc., F. Hoffmann-La Roche AG, Genzyme Corporation, Teva Pharmaceutical Industries Ltd., Celgene Corporation, Genmab A/S and AstraZeneca plc.
KEY MARKET BENEFITS:
- Comprehensive analysis of factors that drive and restrict the growth of the global chronic lymphocytic leukemia therapeutics market is provided
- The report provides a comprehensive analysis of the current market and estimations through 20142020, which would enable the stakeholders to capitalize on prevailing market opportunities
- An in-depth analysis of key segments of the market demonstrate the types of drugs along with routes of administration in the CLL therapeutics market
- An in-depth analysis of key segments of the market demonstrates the types of drugs and routes of administration that are currently being used along with the variants that would gain prominence in future
- SWOT analysis enables to study the internal environment of the leading companies for strategy formulation
- Region-wise Chronic Lymphocytic Leukemia Therapeutics market scenario is comprehensively analyzed in the report
KEY MARKET SEGMENTS:
The global Chronic Lymphocytic Leukemia Therapeutics market is segmented below:
Chronic Lymphocytic Leukemia Therapeutics Market By Drug Type
- Chemotherapy Drugs
- Targeted Therapy
- Approved Drugs
- Pipeline Drugs
- Others
Chronic Lymphocytic Leukemia Therapeutics Market By Route of Administration
- Oral Drugs
- Intravenous Drugs
- Others
Chronic Lymphocytic Leukemia Therapeutics Market By Geography
- North America
- Europe
- AsiaPacific
- LAMEA
We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:
- Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
- Technologically sophisticated and reliable insights through well audited and veracious research methodology
- Sovereign research proceeds that present a tangible depiction of marketplace
With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.
Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry
- Patent and regulatory databases for understanding of technical & legal developments
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic new articles, web-casts and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast
Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:
- Validates and improves the data quality and strengthens research proceeds
- Further develops analyst team’s market understanding and expertise
- Supplies authentic information about market size, share, growth and forecasts
Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:
- Chief executives and VPs of leading corporations specific to industry
- Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)
Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.
REQUEST TOC/SAMPLE
Purchase Full Report of
World Chronic Lymphocytic Leukemia Therapeutics Market-
Opportunities and Forecasts, 2014 -2022
- Online Only
-
$3,456$3,110 - Online cloud access only
- Restricted print, copy, paste & download
- Read only
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
- Data Pack
-
$3,840$3,456 - Restricted to one authorized user
- One print only
- Available in
Excel - Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
- Single User
-
$5,769$5,192 - Restricted to one authorized user
- One print only
- Available in Excel & PDF
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
- Five Users
-
$6,450$5,805 - Limited to five authorized users
- Print upto five copies
- Available in Excel & PDF
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
-
Enterprise
License/PDF -
$8,995$8,096 - Unlimited
within
company/enterprise - Available in Excel & PDF
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
- Library Membership
- $0.00
- Published Content
E-access - Company Profiles
E-access - Newly Added Content Access
- 10 PDF
Downloads - 5 Excel Data
Pack Downloads - 250 Company Profiles PDF Downloads
-
Start reading.
Buy Now
This title and over 12,000+ are available on the Avenue Library. Subscription @ $699 T&C*.
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
Why Allied Market Research?
Infallible Methodology
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
Analyst Support
For complete satisfaction
Customization
On-demand customization of scope of the report to exactly meet your needs
TARGETED MARKET VIEW
Targeted market view to provide pertinent information and save time of readers
Get fresh content delivered
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.